These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26981618)

  • 1. Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics.
    Henry SP; Seguin R; Cavagnaro J; Berman C; Tepper J; Kornbrust D
    Nucleic Acid Ther; 2016 Aug; 26(4):210-5. PubMed ID: 26981618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.
    Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ
    J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.
    Henry SP; Jagels MA; Hugli TE; Manalili S; Geary RS; Giclas PC; Levin AA
    Nucleic Acid Ther; 2014 Oct; 24(5):326-35. PubMed ID: 25093529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.
    Henry SP; Beattie G; Yeh G; Chappel A; Giclas P; Mortari A; Jagels MA; Kornbrust DJ; Levin AA
    Int Immunopharmacol; 2002 Nov; 2(12):1657-66. PubMed ID: 12469940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorothioate oligonucleotides: effectiveness and toxicity.
    Iannitti T; Morales-Medina JC; Palmieri B
    Curr Drug Targets; 2014; 15(7):663-73. PubMed ID: 24655142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
    Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
    Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
    Henry SP; Templin MV; Gillett N; Rojko J; Levin AA
    Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide.
    Frazier KS; Sobry C; Derr V; Adams MJ; Besten CD; De Kimpe S; Francis I; Gales TL; Haworth R; Maguire SR; Mirabile RC; Mullins D; Palate B; Doorten YP; Ridings JE; Scicchitano MS; Silvano J; Woodfine J
    Toxicol Pathol; 2014 Jul; 42(5):923-35. PubMed ID: 24292388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorothioates, essential components of therapeutic oligonucleotides.
    Eckstein F
    Nucleic Acid Ther; 2014 Dec; 24(6):374-87. PubMed ID: 25353652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of coagulation by a phosphorothioate oligonucleotide.
    Henry SP; Novotny W; Leeds J; Auletta C; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):503-10. PubMed ID: 9361909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.
    Black LE; Farrelly JG; Cavagnaro JA; Ahn CH; DeGeorge JJ; Taylor AS; DeFelice AF; Jordan A
    Antisense Res Dev; 1994; 4(4):299-301. PubMed ID: 7734946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
    Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
    J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2'-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF.
    Shen W; Liang XH; Sun H; Crooke ST
    Nucleic Acids Res; 2015 May; 43(9):4569-78. PubMed ID: 25855809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.
    Hamad I; Hunter AC; Szebeni J; Moghimi SM
    Mol Immunol; 2008 Dec; 46(2):225-32. PubMed ID: 18849076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unlocking P(V): Reagents for chiral phosphorothioate synthesis.
    Knouse KW; deGruyter JN; Schmidt MA; Zheng B; Vantourout JC; Kingston C; Mercer SE; Mcdonald IM; Olson RE; Zhu Y; Hang C; Zhu J; Yuan C; Wang Q; Park P; Eastgate MD; Baran PS
    Science; 2018 Sep; 361(6408):1234-1238. PubMed ID: 30072577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
    Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP
    Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.